TB vaccination could be overall cost-effective in 73 of 105 LMICs (70%) and produce economic benefits of US $474 billion by 2050, per modelling study by researchers at Harvard, LSHTM, the WHO and IAVI (IMAGE)
Caption
Incremental net monetary benefit of novel tuberculosis vaccines assessed from the societal perspective, for several willingness-to-pay thresholds. Note: Estimates include the iNMB from the countries that are cost-effective at the respective threshold. GDP per capita estimates from 2020. GDP, gross domestic product per capita; iNMB, incremental net monetary benefit.
Credit
Portnoy A, et al., 2023, PLOS Medicine, CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)
Usage Restrictions
Credit must be given to the creator.
License
CC BY